Dinutuximab: A Novel Immunotherapy in the Treatment of Pediatric Patients With High-Risk Neuroblastoma [Formula: see text].

Bartholomew, Joy; Washington, Tanea; Bergeron, Sharon; Nielson, Danelle; Saggio, Jennifer; Quirk, Lindsay

Bartholomew, Joy; Washington, Tanea; Bergeron, Sharon; Nielson, Danelle; Saggio, Jennifer; Quirk, Lindsay.

Afiliação

Bartholomew J; 1 Children's Mercy Hospital Kansas City, Kansas City, MI, USA.
Washington T; 2 Children's Hospital Los Angeles, Los Angeles, CA, USA.
Bergeron S; 3 Children's Hospital of Orange County, Los Angeles, CA, USA.
Nielson D; 4 Primary Children's Hospital, Salt Lake City, UT, USA.
Saggio J; 5 Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Quirk L; 2 Children's Hospital Los Angeles, Los Angeles, CA, USA.

J Pediatr Oncol Nurs ; 34(1): 5-12, 2017.

Article em En | MEDLINE | ID: mdl-27456981

RESUMO

Therapy combining dinutuximab with granulocyte macrophage colony stimulating factor, interleukin 2, and isotretinoin has significant side effects; however, these complications are generally predictable and can be managed proactively.

Palavras-chave

immunotherapy; infusion management; patient safety

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Pediatr Oncol Nurs Assunto da revista: ENFERMAGEM / NEOPLASIAS / PEDIATRIA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google